64 completed, 21 terminated, 21 unknown, 20 recruiting. 68 Phase 2, 52 Phase 1, 14 Phase 3, 11 Not applicable, 1 Early Phase 1.
Follow Primary Peritoneal Carcinoma: new trials by email Literature Review of Primary Peritoneal Carcinoma trials Research Report on Primary Peritoneal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer Fimbriectomy Followed by Delayed Oophorectomy (F-DO), Bilateral Salpingo-Oophorectomy - Tubo-ovarian Carcinoma, High-grade Serous Carcinoma | Not applicable | Not yet recruiting | Centre Oscar Lambret | 1100 | 2027-03-01 | 2026-03-17 |
| IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 2 | Recruiting | University of Washington | 26 | 2026-09-16 | 2026-09-21 |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 19 | 2026-07-01 | 2026-06-30 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-02-04 | 2026-03-18 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance Ovarian Cancer, Fallopian Tube Cancers | Not yet recruiting | Tongji Hospital | 600 | 2025-11-27 | 2025-12-08 | |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-05 |
| Surgery for Relapsed Ovarian Cancer in Precision surgery/chemotherapy, Iparomlimab/Tuvonralimab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 33 | 2025-07-01 | 2025-06-27 |
| Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 126 | 2025-05-22 | 2025-07-02 |
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment Non-Interventional Study - Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection | Completed | Mayo Clinic | 49 | 2025-03-07 | 2025-12-04 | |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | North Eastern German Society of Gynaecological Oncology | 640 | 2024-10-11 | 2026-07-27 |
| Diet, Hepcidin, and Chemotherapy RDI Breast Cancer Female, Ovarian Cancer | Active not recruiting | George Washington University | 100 | 2024-08-16 | 2026-01-29 | |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers 27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2024-08-06 | 2026-02-03 |
| Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers Best Practice, Cilostazol, Cryocompression Therapy - Cervical Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Emory University | 70 | 2024-08-01 | 2026-08-27 |
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression RC48+carboplatin±bevacizumab - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 54 | 2024-05-16 | 2026-10-01 |
| A Study of Sovilnesib in Subjects With Ovarian Cancer Sovilnesib - High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer | Phase 1 | Recruiting | Volastra Therapeutics, Inc. | 150 | 2024-04-04 | 2026-10-13 |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi Fluzoparib, Fluzoparib+Apatinib - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Unknown | Guangxi Medical University | 80 | 2023-12-10 | 2023-12-07 |
Showing 20 of 150. Sign in to see all of them.
Fallopian Tube Neoplasms (123) · Ovarian Neoplasms (121) · Carcinoma, Ovarian Epithelial (31) · Endometrial Neoplasms (15) · Uterine Cervical Neoplasms (14) · Breast Neoplasms (13) · Recurrence (10) · Carcinoma, Non-Small-Cell Lung (9) · Stomach Neoplasms (9) · Carcinoma, Renal Cell (8) · Colorectal Neoplasms (8) · Lung Neoplasms (7) · Uterine Neoplasms (7) · Cholangiocarcinoma (6) · Triple Negative Breast Neoplasms (6)
Neoplasms by Site (144) · Adnexal Diseases (143) · Female Urogenital Diseases (143) · Female Urogenital Diseases and Pregnancy Complications (143) · Genital Diseases (143) · Genital Diseases, Female (143) · Genital Neoplasms, Female (143) · Urogenital Diseases (143) · Urogenital Neoplasms (143) · Neoplasms (142) · Endocrine Gland Neoplasms (134) · Endocrine System Diseases (134) · Gonadal Disorders (134) · Ovarian Diseases (133) · Fallopian Tube Diseases (123)
Paclitaxel (25) · Carboplatin (21) · Bevacizumab (17) · Taxes (10) · Cisplatin (9) · Cyclophosphamide (9) · pembrolizumab (7) · Hyperthermic Intraperitoneal Chemotherapy (6) · Topotecan (6) · liposomal doxorubicin (6) · Magnetic Resonance Spectroscopy (5) · Neoadjuvant Therapy (5) · niraparib (5) · olaparib (5) · Chemotherapy, Adjuvant (4)
Gynecologic Oncology Group (16) · Shanghai Gynecologic Oncology Group (10) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · Dana-Farber Cancer Institute (4) · Memorial Sloan Kettering Cancer Center (4) · Washington University School of Medicine (3) · Beijing Biotech (2) · Celldex Therapeutics (2) · Lyell Immunopharma, Inc. (2) · Mayo Clinic (2) · North Eastern German Society of Gynaecological Oncology (2) · OncoC4, Inc. (2) · Roswell Park Cancer Institute (2) · Seoul National University Hospital (2)
United States (102) · China (21) · Canada (8) · Germany (8) · Italy (8) · United Kingdom (8) · France (7) · Spain (7) · Belgium (5) · South Korea (5) · Australia (4) · Ireland (3) · Austria (2) · Czechia (2) · Hong Kong (2)
Rongyu Zang, MD,PhD (3) · Emese Zsiros, MD (2) · Jackie Walling, MBChB, PhD (2) · Robert Edwards (2) · Shuzhong Cui, M.D (2) · Zhongqiu Lin, M.D (2) · Agnieszka Michael, MBBS PhD (1) · Agustin Garcia (1) · Alexi A. Wright, MD (1) · Amanika Kumar, MD (1) · Amina Ahmed (1) · Amit Oza (1) · Amit Oza, M.D. (1) · Amy Tiersten (1)
PMID 37185961, PMID 27246305, PMID 36459691, PMID 11181662, PMID 16368439, PMID 16394300, PMID 19058838, PMID 20022092, PMID 20818904, PMID 21276234, PMID 22960352, PMID 23261356, PMID 23747291, PMID 23969788, PMID 24779680, PMID 25016924, PMID 25667285, PMID 25827290, PMID 26002111, PMID 26051335, PMID 26091936, PMID 27502591, PMID 27601552, PMID 29115086, PMID 29342393, PMID 30633128, PMID 31069579, PMID 31350251, PMID 31383985, PMID 31639066, PMID 31708167, PMID 32319233, PMID 32808504, PMID 33433743, PMID 33610319, PMID 33667670, PMID 33705695, PMID 33909232, PMID 34055086, PMID 34132071, PMID 34562230, PMID 34965890, PMID 34986897, PMID 35130043, PMID 35382842, PMID 36214786, PMID 36410913, PMID 37129197, PMID 37148580, PMID 37229879
U10CA027469 (16), U10CA101165 (4), U10CA180868 (4), 2017 (1), 2019 (1), 2023 (1), N01CM17101 (1), N01CM17107 (1), N01CM62203 (1), P30CA013330 (1), P30CA016056 (1), P30CA033572 (1), P30CA138292 (1), P50CA136393 (1), R01CA249329 (1)